URGN
UroGen Pharma Ltd. NASDAQ$23.29
Mkt Cap $1.1B
52w Low $3.42
74.8% of range
52w High $30.00
50d MA $20.40
200d MA $20.47
P/E (TTM)
-7.2x
EV/EBITDA
-8.4x
P/B
—
Debt/Equity
-1.2x
ROE
145.5%
P/FCF
-6.9x
RSI (14)
—
ATR (14)
—
Beta
1.44
50d MA
$20.40
200d MA
$20.47
Avg Volume
806.5K
About
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III …
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | AMC | -0.52 | -0.54 | -4.2% | 19.02 | +2.7% | -1.1% | +6.0% | +3.1% | +7.6% | +4.7% | — |
| Nov 6, 2025 | AMC | -0.72 | -0.69 | +4.2% | 23.54 | -3.9% | -1.3% | -1.7% | +0.4% | +6.8% | +1.6% | — |
| Aug 7, 2025 | AMC | -0.82 | -1.05 | -28.0% | 18.59 | +2.0% | -4.5% | -1.9% | +3.3% | +8.2% | +8.0% | — |
| May 12, 2025 | AMC | -0.83 | -0.92 | -10.8% | 11.14 | +0.0% | -9.0% | -11.4% | -11.6% | -34.4% | -28.5% | — |
| Mar 10, 2025 | AMC | -0.69 | -0.80 | -15.9% | 9.92 | -1.5% | +9.1% | +9.1% | +9.9% | +11.6% | +15.4% | — |
| Nov 6, 2024 | AMC | -0.84 | -0.55 | +34.5% | 12.24 | +0.0% | -1.1% | -1.0% | +4.5% | +0.9% | -0.7% | — |
| Aug 13, 2024 | AMC | -0.82 | -0.91 | -11.0% | 14.96 | +2.7% | -0.1% | +3.5% | -1.1% | -1.6% | +0.3% | — |
| May 13, 2024 | AMC | -0.93 | -0.97 | -4.3% | 13.07 | -2.5% | -0.8% | +5.4% | +1.1% | +1.1% | -1.2% | — |
| Mar 14, 2024 | AMC | -0.67 | -0.72 | -7.5% | 14.33 | +1.1% | +0.9% | +1.2% | +4.8% | +4.4% | +4.3% | — |
| Nov 14, 2023 | AMC | -0.89 | -0.68 | +23.6% | 11.68 | -1.1% | -0.9% | +2.7% | +6.7% | +6.4% | +8.5% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31 | D. Boral Capital | Maintains | Buy → Buy | — | $17.00 | $17.36 | +2.1% | +5.8% | +11.4% | +10.7% | +9.5% | +6.1% |
| Mar 2 | D. Boral Capital | Maintains | Buy → Buy | — | $21.70 | $21.66 | -0.2% | -12.4% | -13.3% | -7.1% | -9.6% | -5.7% |
| Jan 23 | D. Boral Capital | Maintains | Buy → Buy | — | $20.00 | $19.76 | -1.2% | +0.0% | +5.4% | +9.2% | +6.6% | +3.5% |
| Jan 5 | D. Boral Capital | Maintains | Buy → Buy | — | $22.71 | $22.59 | -0.5% | -2.6% | -3.6% | +1.9% | +3.3% | -6.4% |
| Oct 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.97 | $19.00 | +0.2% | +9.9% | +6.4% | +4.3% | +4.6% | +7.9% |
| Oct 27 | D. Boral Capital | Maintains | Buy → Buy | — | $18.97 | $19.00 | +0.2% | +9.9% | +6.4% | +4.3% | +4.6% | +7.9% |
| Oct 3 | D. Boral Capital | Maintains | Buy → Buy | — | $17.07 | $17.25 | +1.1% | +1.9% | -0.1% | -1.3% | +1.5% | -3.8% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.75 | $17.48 | -1.5% | +2.8% | +8.2% | +13.3% | +13.1% | +11.0% |
| Aug 7 | D. Boral Capital | Maintains | Buy → Buy | — | $20.01 | $19.33 | -3.4% | -7.1% | -11.3% | -8.8% | -4.0% | +0.5% |
| Aug 5 | D. Boral Capital | Maintains | Buy → Buy | — | $19.88 | $19.92 | +0.2% | +4.2% | +0.7% | -6.5% | -10.7% | -8.2% |
Recent Filings
8-K
UroGen Pharma Ltd. -- 8-K Filing
UroGen Pharma reported accelerating physician adoption and uptake metrics for its urothelial cancer treatments in Q4 2025, signaling commercial momentum for its product launches.
Mar 2
8-K · 1.01
! Medium
UroGen Pharma Ltd. -- 8-K 1.01: Financing / Debt Agreement
UroGen Pharma secured financing through an agreement with BPCR Limited Partners, providing capital to support operations and strategic initiatives.
Mar 2
Data updated apr 27, 2026 6:59am
· Source: massive.com